Exploiting collateral sensitivity controls growth of mixed culture of sensitive and resistant cells and decreases selection for resistant cells in a cell line model

BACKGROUND: CDK4/6 inhibitors such as ribociclib are becoming widely used targeted therapies in hormone-receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2−) breast cancer. However, cancers can advance due to drug resistance, a problem in which tumor heterogeneity and evo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Cell Int
Main Authors: Grolmusz, Vince Kornél, Chen, Jinfeng, Emond, Rena, Cosgrove, Patrick A., Pflieger, Lance, Nath, Aritro, Moos, Philip J., Bild, Andrea H.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Primary Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7301982/
https://ncbi.nlm.nih.gov/pubmed/32565737
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12935-020-01337-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados